{"id":"vectical-ointment","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation at application site"},{"rate":null,"effect":"Hypercalcemia (with excessive use)"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL2108523","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcitriol, the active ingredient in Vectical, is a potent vitamin D3 analog that activates the vitamin D receptor (VDR) on keratinocytes and immune cells in the skin. This activation promotes normal cell differentiation, reduces inflammatory cytokine production, and suppresses the abnormal keratinocyte proliferation characteristic of psoriasis. The topical formulation delivers the drug directly to affected skin areas while minimizing systemic absorption.","oneSentence":"Vectical is a topical vitamin D3 analog that binds to vitamin D receptors in skin cells to promote differentiation and reduce excessive proliferation in psoriasis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:23.817Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis (topical treatment)"}]},"trialDetails":[{"nctId":"NCT00658788","phase":"PHASE3","title":"Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-03","conditions":"Psoriasis","enrollment":305},{"nctId":"NCT00988637","phase":"PHASE4","title":"Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-10","conditions":"Plaque Psoriasis","enrollment":138},{"nctId":"NCT00419666","phase":"PHASE2","title":"A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-08-01","conditions":"Chronic Plaque Psoriasis","enrollment":25},{"nctId":"NCT02186665","phase":"PHASE4","title":"Plaque Psoriasis Study in Pediatric Subjects","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2014-07","conditions":"Plaque Psoriasis","enrollment":19},{"nctId":"NCT01766440","phase":"PHASE4","title":"PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-03","conditions":"Plaque Psoriasis","enrollment":18},{"nctId":"NCT02125279","phase":"PHASE4","title":"Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2014-05","conditions":"Psoriasis Vulgaris","enrollment":54},{"nctId":"NCT03140449","phase":"PHASE3","title":"Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2013-09-05","conditions":"Facial Angiofibroma","enrollment":52},{"nctId":"NCT01012713","phase":"PHASE4","title":"Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-06","conditions":"Chronic Stable Plaque Psoriasis","enrollment":30},{"nctId":"NCT01358045","phase":"PHASE2","title":"Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-11","conditions":"Basal Cell Carcinoma","enrollment":128},{"nctId":"NCT01388517","phase":"PHASE4","title":"Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2008-01","conditions":"Pityriasis Alba","enrollment":39},{"nctId":"NCT01205880","phase":"PHASE4","title":"Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis","status":"COMPLETED","sponsor":"Emer, Jason, M.D.","startDate":"2009-12","conditions":"Psoriasis","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DEVICE MALFUNCTION"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"FATIGUE"}],"_approvalHistory":[],"publicationCount":390,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vectical Ointment","genericName":"Vectical Ointment","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vectical is a topical vitamin D3 analog that binds to vitamin D receptors in skin cells to promote differentiation and reduce excessive proliferation in psoriasis. Used for Plaque psoriasis (topical treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}